|
Lpez-Cuenca N., Marn F., Roldn V., Gonzlez-Conejero R., Hernndez-Romero D., Valdés M., Lip G.Y.H. Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. Annals of Medicine. December 2010. 42:562-575. 10.3109/07853890.2010.507601
AÑO: 2010; IF: 4.323
|
|
Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marín F; European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost. 2010 Jan;103(1):13-28. doi: 10.1160/TH09-08-0580. Epub 2009 Sep 30. Review. Erratum in: Thromb Haemost. 2010 Sep;104(3):653. Dosage error in article text. PubMed PMID: 20062939.
AÑO: 2010; IF: 4.701
|
|
Marín F., Bonacasa B., Valdés M. Glycoprotein inhibitors in patients on chronic anticoagulation: Safe enough or too much risk?. Thrombosis and Haemostasis. January 2010. 103:11-12. 10.1160/TH09-10-0694
AÑO: 2010; IF: 4.701
|
|
Pineda J, Marín F, Marco P, Roldán V, Valencia J, Ruiz-Nodar JM, Romero DH, Sogorb F, Lip GY. The prognostic value of biomarkers after a premature myocardial infarction. Int J Cardiol. 2010 Sep 3;143(3):249-54. doi: 10.1016/j.ijcard.2009.02.019. Epub 2009 Mar 17. PubMed PMID: 19278741.
AÑO: 2010; IF: 6.802
|
|
Tello-Montoliu A, Marín F, Roldán V, Lip GY. The additive value of biomarkers to clinical risk scores in acute coronary syndrome. Are biomarkers really ready for real world usage? Heart. 2010 Feb;96(3):227-8; author reply 228. doi: 10.1136/hrt.2009.182105. PubMed PMID: 20133421.
AÑO: 2010; IF: 4.708
|